Ana Aitawa, Manager, iHealthcareAnalyst Inc.10.25.18
The global sales of transdermal drug delivery systems (TDDS) are expected to increase at a compound annual growth rate (CAGR) of 2.4 percent over the forecast period 2018 to 2023.
The key TDDS market drivers include unmet medical need, advancement in drug delivery technology, and various advantages, such as prolonged therapeutic effect, reduced side-effects, improved bioavailability, better patient compliance, and easy termination of drug therapy. The large surface area and accessibility of the skin make it a convenient and patient-friendly target for drug delivery. The majority of TDDS on the market are based on passive diffusion, whereas the most active technologies are in clinical development and subsequent regulatory processes.
The market growth limiters include strong competition from advanced oral pharmaceuticals, a relatively small number of transdermal drug products in the market, allergic reactions, and availability of other lower-cost and longer-acting treatment options.
Pain management applications accounted for over 50 percent of global sales of transdermal patches, targeting conditions such as acute and chronic pain. The global market for analgesic patch systems [fentanyl (Duragesic), lidocaine (Lidoderm), and buprenorphine (Butrans)] for pain management has increased significantly, owing to its high demand and larger acceptance by physicians and patients, and higher incidence of skin cancer.
Increasing prevalence of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, attention deficit hyperactivity disorder (ADHD), and major depressive disorders (MDD) are likely to increase relative market share for patch-based neurological disorder treatment products over the next five-year period.
Cardiovascular disease (CVD) segment [clonidine (Catapres-TTS) and nitroglycerin (Nitro-Dur) patches for the management of angina pectoris and resistant hypertension] is expected to grow at a CAGR of 3.3 percent over the forecast period. Factors contributing to growth in the CVD market include increasing aging population coupled with high incidence of obesity leading to increased prevalence of hypertension and CVD-related diseases (such as angina pectoris) among the global population.
The North American region (U.S., Canada) accounted for over 75 percent of the global patch-based transdermal systems market followed by five major European countries. The U.S. is expected to dominate the global market considering the high incidence of skin diseases (such as psoriasis, eczema, and skin cancer), increasing preference towards pain-free drug delivery methods, and launch of new topical products.
The three leading competitors—Mylan N.V., Novartis AG, and Noven Therapeutics (Hisamitsu Pharmaceutical Co., Inc.)—accounted for more than 90 percent of the global transdermal patches revenues. Other players in the TDDS market are 3M Drug Delivery Systems, Allergan Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Acrux Limited, Echo Therapeutics Inc., and Endo Pharmaceuticals Inc.
The key TDDS market drivers include unmet medical need, advancement in drug delivery technology, and various advantages, such as prolonged therapeutic effect, reduced side-effects, improved bioavailability, better patient compliance, and easy termination of drug therapy. The large surface area and accessibility of the skin make it a convenient and patient-friendly target for drug delivery. The majority of TDDS on the market are based on passive diffusion, whereas the most active technologies are in clinical development and subsequent regulatory processes.
The market growth limiters include strong competition from advanced oral pharmaceuticals, a relatively small number of transdermal drug products in the market, allergic reactions, and availability of other lower-cost and longer-acting treatment options.
Pain management applications accounted for over 50 percent of global sales of transdermal patches, targeting conditions such as acute and chronic pain. The global market for analgesic patch systems [fentanyl (Duragesic), lidocaine (Lidoderm), and buprenorphine (Butrans)] for pain management has increased significantly, owing to its high demand and larger acceptance by physicians and patients, and higher incidence of skin cancer.
Increasing prevalence of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, attention deficit hyperactivity disorder (ADHD), and major depressive disorders (MDD) are likely to increase relative market share for patch-based neurological disorder treatment products over the next five-year period.
Cardiovascular disease (CVD) segment [clonidine (Catapres-TTS) and nitroglycerin (Nitro-Dur) patches for the management of angina pectoris and resistant hypertension] is expected to grow at a CAGR of 3.3 percent over the forecast period. Factors contributing to growth in the CVD market include increasing aging population coupled with high incidence of obesity leading to increased prevalence of hypertension and CVD-related diseases (such as angina pectoris) among the global population.
The North American region (U.S., Canada) accounted for over 75 percent of the global patch-based transdermal systems market followed by five major European countries. The U.S. is expected to dominate the global market considering the high incidence of skin diseases (such as psoriasis, eczema, and skin cancer), increasing preference towards pain-free drug delivery methods, and launch of new topical products.
The three leading competitors—Mylan N.V., Novartis AG, and Noven Therapeutics (Hisamitsu Pharmaceutical Co., Inc.)—accounted for more than 90 percent of the global transdermal patches revenues. Other players in the TDDS market are 3M Drug Delivery Systems, Allergan Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Acrux Limited, Echo Therapeutics Inc., and Endo Pharmaceuticals Inc.
